An international team of clinical collaborators has performed the first-ever clinical test of the targeted therapy avapritinib in paediatric and young...
Vous n'êtes pas connecté
- English
- Français
- عربي
- Español
- Deutsch
- Português
- русский язык
- Català
- Italiano
- Nederlands, Vlaams
- Norsk
- فارسی
- বাংলা
- اردو
- Azərbaycan dili
- Bahasa Indonesia
- Հայերեն
- Ελληνικά
- Bosanski jezik
- українська мова
- Íslenska
- Türkmen, Түркмен
- Türkçe
- Shqip
- Eesti keel
- magyar
- Қазақ тілі
- Kalaallisut ; kalaallit oqaasii
- Lietuvių kalba
- Latviešu valoda
- македонски јазик
- Монгол
- Bahasa Melayu ; بهاس ملايو
- ဗမာစာ
- Slovenščina
- тоҷикӣ ; toğikī ; تاجیکی
- ไทย
- O'zbek ; Ўзбек ; أۇزبېك
- Tiếng Việt
- ភាសាខ្មែរ
- རྫོང་ཁ
- Soomaaliga ; af Soomaali
Maroc - ONCOLOGYNEWS.COM.AU - A La Une - 26/Mar 16:10
CRG-based classification model for IDH1-mutant gliomas
Glioma, the most common primary malignant tumour of the central nervous system, presents significant clinical challenges due to its pronounced intratumoural heterogeneity and poor prognosis. Notably, isocitrate dehydrogenase 1 (IDH1) mutations occur in over 70% of WHO grade II–III gliomas. While patients with IDH1-mutant gliomas generally have better survival outcomes than those with wild-type tumours, [...]
Articles similaires
Potential targeted therapy for paediatric brain cancer identified
oncologynews.com.au - 25/Mar 17:09
An international team of clinical collaborators has performed the first-ever clinical test of the targeted therapy avapritinib in paediatric and young...
New test identifies high-risk childhood brain tumours, improving treatment decisions
oncologynews.com.au - 21/Mar 15:55
Canadian researchers have developed an effective new technique for identifying aggressive medulloblastoma—the most common type of malignant brain...
New test identifies high-risk childhood brain tumours, improving treatment decisions
oncologynews.com.au - 21/Mar 15:55
Canadian researchers have developed an effective new technique for identifying aggressive medulloblastoma—the most common type of malignant brain...
Clinic researchers identify a measurable genetic mutation as a significant predictor of metastasis and survival in pancreatic cancer
oncologynews.com.au - 23/Mar 17:19
A new study by Mayo Clinic Comprehensive Cancer Centre researchers found that the presence of a specific genetic mutation — KRAS circulating...
Federal government invests $30.8M to advance precision oncology for adults with cancer through ‘Precision Oncology Screening Platform Enabling Clinical Trials’ – PrOSPeCT
oncologynews.com.au - 21/Mar 16:04
Omico welcomes the Federal Government’s significant $143.4 million investment in world-leading precision oncology programs—the Zero Childhood...
Federal government invests $30.8M to advance precision oncology for adults with cancer through ‘Precision Oncology Screening Platform Enabling Clinical Trials’ – PrOSPeCT
oncologynews.com.au - 21/Mar 16:04
Omico welcomes the Federal Government’s significant $143.4 million investment in world-leading precision oncology programs—the Zero Childhood...
Alumis, Kaken Pharma ink collaboration & licensing agreement to develop, manufacture and commercialize ESK─001 in dermatology in Japan
pharmabiz.com - 27/Mar 08:51
Alumis Inc, a clinical─stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and...
Scientists Say New Drug Could Help Prevent Alzheimer’s
greekreporter.com - 23/Mar 13:04
An experimental drug has shown promise in preventing Alzheimer’s for people at higher risk of developing the disease. That’s according to a new...
Les derniers communiqués
-
Aucun élément